Antisense & RNAi Therapeutics Market By Technology and Application - Global Industry Analysis & Forecast to 2027
Published On : March 2019 Pages : 150 Category: Pharma & Healthcare Report Code : HC032754
Antisense & RNAi Therapeutics Market By Technology (Antisense RNA, RNA Interference) Application (Cardiovascular, Renal Diseases, Genetic Disorders, Oncology, Respiratory Disorders, Neurodegenerative Disorders, Infectious Diseases, Others) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Antisense & RNAi Therapeutics Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. The worldwide antisense and RNAi therapeutics market have accumulated extensive consideration in the ongoing years attributable to its viewpoint to treat a scope of perpetual maladies, for example, cancer, diabetes, AIDS, tuberculosis, just as certain cardiovascular issues. Notwithstanding being in the clinical research division, the RNA based therapeutics are probably going to be investigated as a most potential treatment decision for the disorders which are hard to treat.
Drivers and Restraints
The rising occurrence of cardiac ailments, coronary artery diseases, and neurodegenerative and irresistible maladies has prompted the interest for antisense and RNai therapeutics. The market displays a solid pipeline of item and is anticipating present a few headways in the RNAi drug delivery technology. These variables will go about as high development rendering drivers in the coming years.
Regional Insights
North America saw to be the most worthwhile market before and has in this way contributed a generous offer to the general division.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Sanofi-Genzyme
- Marina Biosciences
- Benitec Biopharma
- GSK
- Alnylam Pharmaceuticals
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Antisense & RNAi Therapeutics Market, By Technology, Estimates and Forecast, 2017-2027 ($Million)
· Antisense RNA
· RNA Interference
· Antisense & RNAi Therapeutics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
· Cardiovascular
· Renal Diseases
· Genetic Disorders
· Oncology
· Respiratory Disorders
· Neurodegenerative Disorders
· Infectious Diseases
· Others
· Antisense & RNAi Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
· North America
§ North America Antisense & RNAi Therapeutics Market, By Country
o U.S. Antisense & RNAi Therapeutics Market
o Canada Antisense & RNAi Therapeutics Market
o Mexico Antisense & RNAi Therapeutics Market
· Europe
§ Europe Antisense & RNAi Therapeutics Market, By Country
o Germany Antisense & RNAi Therapeutics Market
o UK Antisense & RNAi Therapeutics Market
o France Antisense & RNAi Therapeutics Market
o Russia Antisense & RNAi Therapeutics Market
o Italy Antisense & RNAi Therapeutics Market
o Rest of Europe Antisense & RNAi Therapeutics Market
· Asia-Pacific
§ Asia-Pacific Antisense & RNAi Therapeutics Market, By Country
o China Antisense & RNAi Therapeutics Market
o Japan Antisense & RNAi Therapeutics Market
o South Korea Antisense & RNAi Therapeutics Market
o India Antisense & RNAi Therapeutics Market
o Southeast Asia Antisense & RNAi Therapeutics Market
o Rest of Asia-Pacific Antisense & RNAi Therapeutics Market
· South America
§ South America Antisense & RNAi Therapeutics Market
o Brazil Antisense & RNAi Therapeutics Market
o Argentina Antisense & RNAi Therapeutics Market
o Columbia Antisense & RNAi Therapeutics Market
o Rest of South America Antisense & RNAi Therapeutics Market
· Middle East and Africa
§ Middle East and Africa Antisense & RNAi Therapeutics Market
o Saudi Arabia Antisense & RNAi Therapeutics Market
o UAE Antisense & RNAi Therapeutics Market
o Egypt Antisense & RNAi Therapeutics Market
o Nigeria Antisense & RNAi Therapeutics Market
o South Africa Antisense & RNAi Therapeutics Market
o Rest of MEA Antisense & RNAi Therapeutics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Antisense And RNAi Therapeutics Market, By Technology
5.1. Introduction
5.2. Global Antisense And RNAi Therapeutics Revenue and Market Share by Technology (2017-2027)
5.2.1. Global Antisense And RNAi Therapeutics Revenue and Revenue Share by Technology (2017-2027)
5.3. Antisense RNA
5.3.1. Global Antisense RNA Revenue and Growth Rate (2017-2027)
5.4. RNA Interference
5.4.1. Global RNA Interference Revenue and Growth Rate (2017-2027)
6. Antisense And RNAi Therapeutics Market, By Application
6.1. Introduction
6.2. Global Antisense And RNAi Therapeutics Revenue and Market Share by Application (2017-2027)
6.2.1. Global Antisense And RNAi Therapeutics Revenue and Revenue Share by Application (2017-2027)
6.3. Cardiovascular
6.3.1. Global Cardiovascular Revenue and Growth Rate (2017-2027)
6.4. Renal Diseases
6.4.1. Global Renal Diseases Revenue and Growth Rate (2017-2027)
6.5. Genetic Disorders
6.5.1. Global Genetic Disorders Revenue and Growth Rate (2017-2027)
6.6. Oncology
6.6.1. Global Oncology Revenue and Growth Rate (2017-2027)
6.7. Respiratory Disorders
6.7.1. Global Respiratory Disorders Revenue and Growth Rate (2017-2027)
6.8. Neurodegenerative Disorders
6.8.1. Global Neurodegenerative Disorders Revenue and Growth Rate (2017-2027)
6.9. Infectious Diseases
6.9.1. Global Infectious Diseases Revenue and Growth Rate (2017-2027)
6.10. Others
6.10.1. Global Others Revenue and Growth Rate (2017-2027)
7. Antisense And RNAi Therapeutics Market, By Region
7.1. Introduction
7.2. Global Antisense And RNAi Therapeutics Revenue and Market Share by Regions
7.2.1. Global Antisense And RNAi Therapeutics Revenue by Regions (2017-2027)
7.3. North America Antisense And RNAi Therapeutics by Countries
7.3.1. North America Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2027)
7.3.2. North America Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Antisense And RNAi Therapeutics by Countries
7.4.1. Europe Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2027)
7.4.2. Europe Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Antisense And RNAi Therapeutics by Countries
7.5.1. Asia-Pacific Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Antisense And RNAi Therapeutics by Countries
7.6.1. South America Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2027)
7.6.2. South America Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Antisense And RNAi Therapeutics by Countries
7.7.1. Middle East and Africa Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Sanofi-Genzyme
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Marina Biosciences
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Benitec Biopharma
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. GSK
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Alnylam Pharmaceuticals
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
9. Global Antisense And RNAi Therapeutics Market Competition, by Manufacturer
9.1. Global Antisense And RNAi Therapeutics Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Antisense And RNAi Therapeutics Price By Region (2017-2017)
9.3. Top 5 Antisense And RNAi Therapeutics Manufacturer Market Share
9.4. Market Competition Trend
10. Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.1. Global Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Antisense And RNAi Therapeutics Market Forecast by Regions (2017-2027)
10.2.1. North America Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.1.1. United States Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.1.2. Canada Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.1.3. Mexico Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2. Europe Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.1. Germany Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.2. France Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.3. UK Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.4. Russia Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.5. Italy Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3. Asia-Pacific Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.1. China Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.2. Japan Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.3. Korea Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.4. India Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.4. South America Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.4.1. Brazil Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.4.2. Argentina Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.4.3. Columbia Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.4.4. Rest of South America Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5. Middle East and Africa Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.3. Egypt Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.4. Nigeria Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.5. South Africa Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.6. Turkey Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Antisense And RNAi Therapeutics Market Forecast (2017-2027)
10.3. Antisense And RNAi Therapeutics Market Forecast by Technology (2017-2027)
10.3.1. Antisense And RNAi Therapeutics Forecast by Technology (2017-2027)
10.3.2. Antisense And RNAi Therapeutics Market Share Forecast by Technology (2017-2027)
10.4. Antisense And RNAi Therapeutics Market Forecast by Application (2017-2027)
10.4.1. Antisense And RNAi Therapeutics Forecast by Application (2017-2027)
10.4.2. Antisense And RNAi Therapeutics Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Antisense And RNAi Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Antisense And RNAi Therapeutics Revenue and Revenue Share by Technology (2017-2018)
Figure Global Antisense RNA Revenue and Growth Rate (2017-2018)
Figure Global RNA Interference Revenue and Growth Rate (2017-2018)
Table Global Antisense And RNAi Therapeutics Revenue and Revenue Share by Application (2017-2018)
Figure Global Cardiovascular Revenue and Growth Rate (2017-2018)
Figure Global Renal Diseases Revenue and Growth Rate (2017-2018)
Figure Global Genetic Disorders Revenue and Growth Rate (2017-2018)
Figure Global Oncology Revenue and Growth Rate (2017-2018)
Figure Global Respiratory Disorders Revenue and Growth Rate (2017-2018)
Figure Global Neurodegenerative Disorders Revenue and Growth Rate (2017-2018)
Figure Global Infectious Diseases Revenue and Growth Rate (2017-2018)
Figure Global Others Revenue and Growth Rate (2017-2018)
Table Global Antisense And RNAi Therapeutics Revenue by Regions (2017-2018)
Figure North America Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure North America Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Antisense And RNAi Therapeutics by Countries (2017-2018)
Figure North America Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure United States Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Canada Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Mexico Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Europe Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Antisense And RNAi Therapeutics by Countries (2017-2018)
Figure Europe Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Germany Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure France Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure UK Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Russia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Italy Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Antisense And RNAi Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure China Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Japan Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Korea Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure India Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure South America Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Antisense And RNAi Therapeutics by Countries (2017-2018)
Figure South America Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Brazil Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Argentina Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Columbia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Antisense And RNAi Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Antisense And RNAi Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Antisense And RNAi Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Egypt Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Nigeria Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure South Africa Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Turkey Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antisense And RNAi Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Sanofi-Genzyme Antisense And RNAi Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Marina Biosciences Antisense And RNAi Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Benitec Biopharma Antisense And RNAi Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table GSK Antisense And RNAi Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Alnylam Pharmaceuticals Antisense And RNAi Therapeutics Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Antisense And RNAi Therapeutics Market Share by Manufacturer
Figure Global Antisense And RNAi Therapeutics Revenue and Market Share by Manufacturer
Table Global Antisense And RNAi Therapeutics Price by Region (2017-2017)
Figure Top 5 Antisense And RNAi Therapeutics Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Antisense And RNAi Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Antisense And RNAi Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure United States Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Canada Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Mexico Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Europe Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Germany Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure France Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure UK Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Russia Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Italy Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure China Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Japan Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Korea Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure India Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure South America Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Brazil Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Argentina Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Columbia Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Egypt Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Nigeria Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure South Africa Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Turkey Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Antisense And RNAi Therapeutics Market Forecast (2018-2025)
Figure Global Antisense And RNAi Therapeutics Forecast by Technology (2018-2025)
Figure Global Antisense And RNAi Therapeutics Market Share Forecast by Technology (2018-2025)
Figure Global Antisense And RNAi Therapeutics Forecast by Technology (2018-2025)
Figure Global Antisense And RNAi Therapeutics Forecast by Application (2018-2025)
Figure Global Antisense And RNAi Therapeutics Market Share Forecast by Application (2018-2025)
Figure Global Antisense And RNAi Therapeutics Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|